An antibody's increased tendency to bind itself at high concentrations limits its stability. As such, scientists must carefully characterize self-interaction when selecting molecules for ...

Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will ...

The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...

Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group announced today that the company has accelerated development of a nebulised formulation of its neutralising antibody cocktail treatment, to ...

Bio‑Sourcing and Zerion Pharma A/S today announce that their joint project to develop an oral formulation of Trastuzumab, the pioneer monoclonal antibody used to treat breast cancer, has been awarded ...

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

With the mix of mutations in omicron raising fears the new COVID-19 virus will evade our existing defenses, Celltrion is stepping up work on a nebulized cocktail it thinks may remain effective against ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group announced today it has submitted an Investigational New Drug (IND) application to conduct a global Phase III clinical trial evaluating the ...

Covid-19 vaccinations have tempered the pandemic’s spread in the U.S., but infections are still happening and not everyone is eligible for the authorized shots. Those needing a Covid antibody ...